Compare Natera Inc. Common Stock (NTRA) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while iShares Broad USD Investment Grade Corporate Bond trades at $48.86 (market cap $17.70B). The key difference: Natera Inc. Common Stock is far larger — about 3.2× iShares Broad USD Investment Grade Corporate Bond's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and iShares Broad USD Investment Grade Corporate Bond for 46 Days on average.
| NTRA | USIG | |
|---|---|---|
Market Cap | $57.03B | $17.70B |
Volume | 1,131,157 | 2,181,370 |
Sector | Health | Fixed Income |
52-Week High | $425.64 | $52.69 |
52-Week Low | $179.42 | $48.54 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
USIG trades at $48.84 with minimal daily movement (+0.03%). Technical indicators show a bearish bias with moving averages signaling selling pressure, though oscillators remain neutral. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake. The ETF maintains regular dividend distributions, with recent payments of $0.20-0.21 per share.
The investment grade corporate bond ETF faces headwinds from rising interest rate concerns, though institutional accumulation suggests confidence in its credit quality. Key risks include bond market volatility and credit spread fluctuations. Current technical weakness warrants caution despite the neutral sentiment from oscillators and institutional buying interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
